Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 6,556 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 6,556 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $27.48, for a total value of $180,158.88. Following the completion of the sale, the general counsel now owns 152,361 shares of the company’s stock, valued at approximately $4,186,880.28. This represents a 4.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Phreesia Trading Down 1.8 %

Shares of PHR stock opened at $28.47 on Friday. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The business’s fifty day moving average price is $24.98 and its 200 day moving average price is $23.28. The firm has a market capitalization of $1.65 billion, a PE ratio of -19.37 and a beta of 0.94.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.58) EPS. As a group, sell-side analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PHR shares. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Friday, January 10th. Truist Financial upped their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $33.00 price target (up previously from $31.00) on shares of Phreesia in a report on Wednesday. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Citigroup lifted their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat.com, Phreesia presently has a consensus rating of “Buy” and a consensus target price of $31.15.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC acquired a new stake in shares of Phreesia in the 2nd quarter worth approximately $301,000. Sei Investments Co. grew its holdings in Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after purchasing an additional 95,058 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of Phreesia by 56.3% in the second quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock valued at $5,308,000 after buying an additional 90,215 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Phreesia during the 3rd quarter worth $954,000. Finally, Diversified Trust Co boosted its position in shares of Phreesia by 12.9% in the 3rd quarter. Diversified Trust Co now owns 24,356 shares of the company’s stock worth $555,000 after buying an additional 2,782 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.